Active substance (DCI)
- deutivacaftor
- tezacaftor
- vanzacaftor
Technical information
Manufacturer
VERTEX PHARMACEUTICALS FRANCE
Presentation
ALYFTREK 125 mg/50 mg/10 mg, comprimé pelliculé
plaquette(s) polychlortrifluoroéthylène PVC aluminium de 56 comprimé(s) (CIP : 34009 303 203 8 9)
ALYFTREK 50 mg/20 mg/4 mg, comprimé pelliculé
plaquette(s) polychlortrifluoroéthylène PVC aluminium de 84 comprimé(s) (CIP : 34009 303 203 7 2)
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
Mzhkg09h1yXxCxD8